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Over half a million children are diagnosed with 
tuberculosis (TB) every year. The majority of these 
infections occur in 22 high-burden countries[1] and 
account for 6% of the global TB burden.[2,3] The 
World Health Organization (WHO) reported a 
staggering 74 000 deaths in HIV-negative children <15 years of age 
in 2012 alone, making TB one of the top ten leading causes of death 
in children.[4]
Control programmes are hampered by the increasing spread of 
multidrug-resistant TB (MDR-TB); globally 40 000 new cases of 
MDR-TB are reported annually in paediatric populations.[3] In South 
Africa (SA), children aged ≤14 years are estimated to account for 
approximately 15 - 20% of the total TB disease burden.[5,6]
These global statistics may grossly underestimate the TB burden,[7] 
as microbiological confirmation of TB is challenging in children. 
Typically, the type of specimen obtained for testing depends on the 
age of the child and the clinical presentation.[8] Specimens other 
than sputum most frequently include nasopharyngeal aspirates 
(NPAs), gastric aspirates, induced sputum, throat swabs, fine-needle 
lymph node aspiration, bone marrow, urine, stool and aseptic fluids 
(ascitic, pleural and cerebrospinal fluid). With the exception of the 
bone marrow and lymph node, owing to the paucibacillary nature 
of the specimens, multiple sampling over several days is required.[8] 
Additional challenges are often the poor quality[9] and low quantity 
of specimen yield that hamper bacteriological confirmation of 
disease.[10] It is for this reason that no universal diagnostic algorithm 
for TB in children exists, diagnosis relying on a combination of 
clinical signs and nonspecific tests.[7] Clearly, a stronger emphasis 
needs to be placed on advancing the research and development of 
more effective diagnostic strategies for childhood TB detection.
Accurate and sensitive molecular tests such as the GeneXpert 
MTB/RIF assay (Cepheid, USA) (Xpert) are proving that reliable and 
rapid diagnosis of TB can be achieved. The Xpert test was recently 
approved by the US Food and Drug Administration as the first 
moderate complexity test to detect both Mycobacterium tuberculosis 
(MTB) and resistance to rifampicin simultaneously for pulmonary 
TB.[11] In SA, the National Department of Health (NDoH) and 
National Health Laboratory Service (NHLS) have implemented the 
Xpert in 207 smear microscopy centres across the country. Data from 
the programme reflect the Xpert’s sensitivity over microscopy. The 
average national TB positivity rate among presumptive pulmonary 
adult TB cases prior to Xpert was 8%, and this has since increased to 
11% in the fourth year of Xpert use.[12]
The updated Cochrane review on Xpert’s performance in adults 
showed a pooled sensitivity of 98% for smear-positive pulmonary 
TB and 79% for smear-negative TB.[12] In the paediatric population, 
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Background. The GeneXpert MTB/RIF (Cepheid, USA) (Xpert) has proved successful for pulmonary tuberculosis (TB) diagnosis on 
decontaminated/concentrated induced sputum specimens from children. Capacity to perform induction in many settings is limited.
Objective. To assess: (i) volumes of ‘routinely obtained’ sputum in a district-level academic hospital; (ii) whether sputum specimens not 
meeting Xpert-required testing volumes could still be tested; and (iii) performance of Xpert on a single paediatric sputum specimen at 
point of care (POC).
Methods. Two sputa were collected from paediatric TB suspects (≤14 years) at Rahima Moosa Mother and Child Hospital, Johannesburg, 
South Africa. One specimen was weighed at POC; if the volume was ≥0.1 mL but <0.5 mL, it was increased to 0.5 mL using saline. 
On-site Xpert testing (G3 cartridge) was performed by a dedicated laboratory technician. The second specimen was referred for TB smear 
microscopy and culture as per standard of care (SOC).
Results. A total of 484 patients presumed to have TB (median age 24 months) were eligible for this study, performed between June 2011 
and May 2012. Xpert could not be used on 4.1% of specimens because of volumes <0.1 mL, and 62.8% required addition of saline prior to 
Xpert testing. Xpert generated a 2.2% error and 3.7% invalid rate, compared with the SOC that rejected 2.3% because of insufficient volume 
and 2.3% that were contaminated. The diagnostic performance compared with culture was 62.5% (95% confidence interval (CI) 24.7 - 91) 
and 99.1% (95% CI 97.4 - 99.8) sensitivity and specificity, respectively, for Xpert (n=345) and 33.3% (7.9 - 69.9) and 99.5% (98.1 - 99.9) 
sensitivity and specificity, respectively, for smear microscopy (n=374).
Conclusions. Up to 67% of ‘routinely obtained’ sputum specimens from children (≤14 years) are below the required volume for Xpert 
testing but can be ‘topped up’ with saline. Xpert MTB/RIF performed better than microscopy and generated clinically relevant, timeous 
results, but sensitivity did not reach the same levels as culture in children.
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studies are limited and most have focused 
on induced sputa,[9,13-16] where sensitivities 
ranging from 33.3%[14] to approximately 
70%[15,17] in smear-negative, culture-positive 
paediatric patients are reported. Increased 
sensitivities of up to 75.9% could be achieved 
if two induced sputa were tested.[14] Further 
studies are now concentrating on alternative 
specimen types such as NPAs,[16] gastric 
lavage aspirates,[18] bronchoalveolar lavage[19] 
and stool.[20,21]
In all Xpert studies on paediatric popu-
lations, specimens underwent laboratory 
decontamination and concentration prior 
to Xpert testing. The aim of this study was 
threefold: (i) to assess the volume of ‘routinely 
obtained’ sputum (i.e. no induced sputum 
facility available) from children ≤14 years 
of age at a district-level academic hospital; 
(ii) to determine whether sputum specimens 
not meeting the Xpert minimum required 
testing volume could be manipulated before 
testing; and (iii) to determine the feasibility 
of performing Xpert MTB/RIF on raw 
paediatric sputum specimens by a dedicated 
staff member, at the point of care (POC).
Methods
Patient recruitment
Paediatric patients accessing care at the 
Rahima Moosa Mother and Child Hospital 
(RMMCH), Johannesburg, SA, were eligible 
for inclusion if their treating clinician 
suspected TB. RMMCH is a district-level 
academic hospital that provides paediatric 
care to the population of the west of 
Johannesburg. The study received approval 
from the University of the Witwatersrand 
Human Ethics Committee (Protocol 
number: M110496).
Study procedures
At the time of the study, the routine 
procedure at RMMCH was to collect two 
sputum specimens; one specimen was sent 
to the NHLS at Helen Joseph Hospital for TB 
smear microscopy and the second specimen 
was sent to the NHLS Braamfontein 
laboratory for liquid culture (MGIT) and 
drug susceptibility testing (DST) when 
necessary. A GeneXpert instrument was 
placed on site in an existing POC laboratory 
designated for sample processing (specimen 
sorting, centrifugation, rapid HIV testing, 
data capture) at RMMCH. This allowed 
specimens to be tested on site.
Specimen collection
A physiotherapist collected two sputum 
specimens concurrently, using clinic standard 
of care methodology, in standard sputum 
collection containers from children ≤14 years 
of age who were suspected of having TB. 
Respiratory samples were obtained following 
administration of chest physiotherapy (at the 
discretion of the individual physiotherapist). 
One of these specimens was randomly 
selected for on-site Xpert testing (G3 
version cartridge) by a trained laboratory 
technician (to replace the first smear) and 
the second specimen was sent to the NHLS 
Braamfontein TB laboratory as per routine, 
for decontamination and concentration 
(NALC-NaOH), smear microscopy, MGIT 
culture and DST, when indicated.
Xpert MTB/RIF testing
Specimens were weighed (in their con-
tainers) on a bench-top precision balance 
(Sigma-Aldrich, USA) to estimate the 
volume of the specimen. If any specimen 
was >0.1 mL but less than the minimum 
required volume of 0.5 mL (estimated at 
0.5 g), sterile saline was added using a stan-
dard Finnpipette (Thermo Fisher Scien tific, 
USA) and sterile pipette tips to increase 
the volume to at least 0.5 mL. Testing of 
specimens on the Xpert MTB/RIF assay was 
performed on the same day as specimen 
collection. However, if any specimen could 
not be tested the same day as a result of 
late specimen receipt, it was stored in a 4oC 
fridge overnight, followed by testing the next 
day as per manufacturer’s instructions. All 
specimens were processed as per standard 
Xpert MTB/RIF protocol by addition of 
Sample Reagent (SR) buffer in a 3:1 or 
2:1 ratio to take the final volume to 2 mL 
(Cepheid, USA). The on-site result obtained 
from the Xpert MTB/RIF assay was reported 
to the treating clinicians.
Statistical analysis
Specimen volumes for Xpert testing were 
described. Non-parametric tests were used 
to determine associations between age and 
volume, Xpert results and volume, and 
age and pre-processing, at 95% confidence 
interval (CI). The sensitivity and specificity 
and positive and negative predictive values 
(PPV and NPV) were calculated for the 
Xpert MTB/RIF assay and smear microscopy 
with a 95% CI using MGIT culture as the 
gold standard.
Results
Data summary
A flow diagram illustrates the processing 
of patient samples (Fig.  1). A total of 484 
eligible children (median age 24 months) 
had samples processed between June 2011 
and May 2012 (interquartile range (IQR) 12 - 
60). Two sputum specimens were collected 
by physiotherapy from 484 patients (none 
required nebulisation); one sample was sent 
for on-site Xpert testing and the other was sent 
for routine laboratory testing. The laboratory 
rejection rate due to insufficient volume 
for smear and culture processing was 2.3% 
(11/484). Culture reported a 2.3% (11/473) 
contamination rate, which was excluded from 
the quantitative analysis (Fig. 1). After study 
commencement, culture and smear results 
for 86 patients could not be retrieved from 
the laboratory information system and were 
therefore excluded from final quantitative 
498 patients
484 eligible patients
484 specimens sent for
smear microscopy and
MGIT culture
484 specimens sent for
on-site Xpert MTB/RIF
Excluded n=14 (>14 years
of age)
Excluded n=11 (rejected,
low volumes (2.3%))
Excluded n=11 (culture
contaminated (2.3%))
Excluded n=86 (culture results
not found (of which 84/86 also
had no smear results))
Excluded n=20 (rejected,
low volumes <0.1 mL
(2.3%))
Excluded n=10 (errors,
(2.2%)); n=17 (invalids
(3.7%))
464 nn-site Xpert
MTB/RIF performed
437 analysable Xpert 
MTB/RIF results
376 analysable
culture results
389 analysable
smear results
Fig. 1. Flow chart of specimen analysis.
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analysis. This coincided with the roll-out of 
the Xpert in SA’s National Programme, which 
commenced in March 2011, whereby the 
diagnostic algorithm for initial TB diagnosis 
changed from collection of two sputum 
specimens to one.
Diagnostic performance analysis
Sputum specimen volumes received from 
children for Xpert testing are shown in 
Table 1. A total of 20/484 specimens (4.1%) 
had sputum volumes of <0.1 mL and could 
not be tested. Of the 464 Xpert tests per-
formed on site, overall error and invalid 
rates of 2.2% (10/464) (1 volume error and 
9  code 5011 errors) and 3.7% (17/464), 
respectively, were reported (Fig. 1).
Using Spearman’s correlation coefficient 
(owing to skewness of the data), an overall 
weak correlation was observed between age 
and volume of specimens received (rho=0.49). 
No association was observed between the 
volume of specimen received and the Xpert 
result (p=0.14). However, an association 
was observed between age and Xpert results 
(p=0.004), with more TB-positives detected in 
the older age group (median age 132 months).
While prior specimen manipulation by 
addition of sterile saline before Xpert testing 
did not affect the error/invalid rate (p=0.19) 
reported on the Xpert, more positive results 
were generated from specimens that did not 
require the addition of saline; however, this 
did not reach significance (p=0.18).
Table 2 further categorises the specimens 
by age and volume and details the per-
formance by Xpert compared with liquid 
culture as the reference. Sputum volume 
clearly increased with age and it appears that, 
on average, specimens from children aged 
≥25 months would require less addition of 
saline prior to Xpert testing. The minimum 
age group in which MTB was detected by 
Xpert was 13 months, with total reported 
MTB positivity of 2.7% (12/437).
Smear microscopy also only detected MTB 
from 13 months onwards, reporting 7/389 
positive specimens (1.8%) (Table 3). MGIT 
culture initially reported a positivity rate of 
4.0% (15/376); however, after follow-up DST in 
all culture-positive specimens using the Hain 
MTBDrplus version 1 assay (Hain LifeScience, 
GmbH, Germany), only 9/15 were confirmed 
as MTB complex (2.4%) (Table 3). The other 
six specimens were probably non-tuberculosis 
mycobacteria, but were not definitively 
identified. Culture remained most sensitive in 
detecting MTB in the lower age group, detecting 
1 positive in each age group <24 months and 6 
positives in the >60-month category.
Performance data for MGIT culture, 
smear microscopy and the Xpert MTB/RIF 
are shown in Table 3.
Smear microscopy was able to identify 3 of 
the 9 culture-confirmed MTB-positive cases 
but additionally reported 2 culture-negative 
(and Xpert-negative) specimens as positive. 
Compared with culture on 374 specimens, 
smear generated a sensitivity and specificity 
of 33.3% (95% CI 7.9 - 69.9) and 99.5% 
(95% CI 98.1 - 99.9), respectively. Relative 
to smear, Xpert detected 3 additional MTB-
positive cases.
Of the 12 Xpert-positive cases reported, 
corresponding culture results could not 
be found in 4 cases. Xpert detected 5/9 
culture-confirmed MTB-positive specimens 
and an additional 3 cases. Analysis of 345 
patients with both Xpert and culture results 
demonstrated an Xpert sensitivity of 62.5% 
(95% CI 24.7 - 91) and high specificity of 
99%. Overall the Xpert was able to detect 
66.7% of smear-positive, culture-positive 
cases (2/3) and 50% of smear-negative, 
culture-positive cases (3/6).
The Xpert MTB/RIF reported only a 
single specimen (8.3%, 1/12) with rifampicin 
resistance, but the MTBDRplus v1 reported 
rifampicin and isoniazid susceptibility in 
this specimen. Two additional specimens 
were reported mono-isoniazid-resistant by 
MTBDrplus v1.
Discussion
Moving the Xpert MTB/RIF assay to the 
POC has been shown to be feasible, to save 
Table 2. Diagnostic performance of the Xpert MTB/RIF assay stratified by age of child
0 - 6 months 7 - 12 months 13 - 24 months 25 - 60 months >60 months
Diagnostic performance of Xpert stratified by 
age (N=437)
 Specimens per age group, n 55 122 81 67 112
 Age (months), median (IQR) 4 (3 - 5) 12 (9 - 12) 24 (24 - 24) 48 (36 - 60) 96 (84 - 132)
 Volume of sputum (mL), mean (SD) 0.21 (0.17) 0.28 (0.22) 0.37 (0.42) 0.58 (0.80) 1.04 (0.86)
Xpert positives, n (%) 0 0 1 (1.2) 0 11 (9.8)
Xpert performance stratified by age v. culture 
(N=345)
 Sensitivity, % (95% CI) 0 (0 - 97.5) 0 (0 - 97.5) 100 (2.5 - 100) - 66.7 (22.3 - 95.7
 Specificity, % (95% CI) 100 (91.2 - 100) 98.9 (94.5 - 99.9) 100 (94.8 - 100) 100 (92.6 - 100) 97.5 (91.4 - 99.7)
PPV, % (95% CI) - 0 (0 - 97.5) 100 (2.5 - 100) - 66.7 (22.3 - 95.7)
NPV, % (95% CI) 97.6 (87.1 - 99.9) 98.9 (94.5 - 99.9) 100 (94.8 - 100) 100 (92.6 - 100) 97.3 (91.4 - 99.7)
Table 1. Volumes of sputum specimens used for on-site Xpert MTB/RIF testing
Specimen volumes received for Xpert (N=484)
<0.1 mL 0.1 - 0.4 mL 0.5 - 4 mL Statistic
Specimens, n (%) 20 (4.1) 304 (62.8) 160 (33.1)
Age of patients 
(months), median (IQR) 12 (9 - 24) 12 (9 - 24) 72 (24 - 108) rho=0.49
Addition of saline Not tested Yes No p=0.19
Xpert-positive, n/total (%) N/A 5/304 (1.6) 7/160 (4.4) p=0.14
Xpert errors, n/total (%) N/A 7/304 (2.3) 3/160 (1.9)
Xpert invalids, n/total (%) N/A 10/304 (3.3) 7/160 (4.4)
} p=0.004
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costs for patients[22] and to have advantages 
over centralised testing, such as same-day 
treatment and shorter time to treatment 
initiation in adult TB suspects.[22-24] Use of 
the Xpert for paediatric TB diagnosis at 
POC may introduce additional challenges. 
Although obtaining an induced sputum 
specimen is a simple and well-tolerated 
procedure,[14] it needs to be conducted by 
a trained healthcare worker. The capacity 
to perform such induction is limited[16] 
and its uptake has been slow. In SA, many 
healthcare facilities are not able to obtain 
respiratory specimens (gastric aspirates or 
sputum) from children and many centres/
clinics lack sputum induction facilities or 
trained healthcare workers to perform the 
procedure. Even when respiratory samples 
are obtained, volumes from children may not 
be sufficient to meet the required minimum 
testing volume needed for the Xpert assay.
The setting where this study was performed 
already had an on-site POC laboratory with 
a trained technician who managed paediatric 
HIV testing and collection of dried blood 
spots, making it feasible for inclusion of 
the GeneXpert technology, especially since 
additional specimen types such as stool 
(under development by Cepheid) and gastric 
or NPAs may in future be tested by Xpert 
at POC.
Data from our study indicate that a large 
proportion (67%) of ‘routinely obtained’ 
sputum specimens received from children 
≤14 years of age are below the minimum 
required testing volume for Xpert and 
could either not be processed (4.1%) or 
required the addition of saline prior to Xpert 
testing (62.8%). Addition of saline required 
weighing the specimen container as an 
estimate of volume and then adding sterile 
saline using a pipette to make up the volume 
to approximately 0.5 mL. This did not affect 
the Xpert result in terms of error/invalid 
rates, but required extra processing time and 
technical training for the person performing 
the testing as well as a supply of sterile 
saline. Volume has previously also been 
shown to have minimal impact on Xpert 
performance.[25] Patient age was associated 
with Xpert result reporting, with more TB 
positives detected in older children. This was 
unrelated to volume of the specimen, but 
probably as a result of a higher bacillary load 
in these patients. However, because of small 
sample numbers, this cannot be definitively 
proven.
The minimum volume of specimen 
required for Xpert testing resulted in twice 
as many specimens not being able to be 
tested by Xpert compared with those sent 
to the laboratory for smear microscopy and 
culture. Xpert also reported an overall error 
plus invalid rate of 5.9%, higher than the 
contamination rate of 2.3% reported with 
culture. The majority of errors were code 
5011, a commonly occurring error on the 
older version G3 cartridges; this has since 
been rectified with the new G4 cartridge.[26]
The positivity rate for MTB in this study 
population was lower than previously 
reported from Cape Town, SA,[14] as expected. 
Similarly to previously reported data,[14,15] 
use of Xpert MTB/RIF on a single sputum 
specimen in our study provided superior 
detection over smear microscopy. The 
Xpert MTB/RIF was able to detect 55% of 
culture-confirmed MTB-positive cases and 
an additional three cases that were negative 
on culture. These three additional cases may 
have been due to the Xpert detecting non-
viable organisms. The moderate sensitivity 
of Xpert compared with culture in our 
study may be due to the fact that specimen 
volumes were too low for testing; of the three 
Xpert false negatives, two were reported on 
specimens <0.5 mL that had needed addition 
of saline prior to Xpert testing. However, 
the wide CI did not allow for an accurate 
estimation of sensitivity and would need a 
larger study cohort. One benefit of this study 
was that an additional 1.6% of TB positives 
could be detected by Xpert by ‘topping up’ 
low-volume specimens instead of discarding 
them. This means that an MTB-positive 
result could be acted on more timeously than 
waiting for a culture result.
The costing of Xpert MTB/RIF for diag-
nosis of smear-negative TB in adults visiting 
a primary healthcare setting in SA has been 
estimated at USD3.28 less than the cost 
per valid smear microscopy plus culture 
result.[27] This study took into account a 
low error rate (of 1%), electricity, water 
and space, medical waste disposal, N-95 
masks, sputum collection bottles and surface 
disinfectant.[27] If Xpert is instituted at POC 
for paediatric/childhood TB diagnosis, it 
will require increased capacity scale-up and 
training (good clinical laboratory practice), 
as well as additional equipment (bench-
top balance, pipettes) and consumables 
(pipette tips, sterile saline). Assessment of 
each individual clinic’s infrastructure needs, 
resources and staff requirements, power 
supply, connectivity and infection control 
will also need to be taken into account.
An advantage of performing on-site Xpert 
testing specifically for children is the rapid 
turnaround of results. However, on-site 
Xpert testing on inadequate specimen 
volumes may increase the chances of 
obtaining errors and invalid results that 
cannot be repeated on the same sample. In 
our study, Xpert MTB/RIF out-performed 
TB microscopy but did not demonstrate 
acceptable sensitivity in this real-world 
setting and cannot currently replace TB 
culture in the diagnosis of paediatric/
childhood TB. Alternative specimen types, 
which are easier to obtain and not subject 
to volume limitations, such as stool, may 
provide a better diagnostic option.
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Table 3. Performance of smear microscopy, MGIT culture (with LPA confirmation) 
and the Xpert MTB/RIF for diagnosis of childhood TB
Culture Smear microscopy Xpert 
Assay performance
Specimens, n 376 389 437
MTB-positive, n (%) 9 (2.4) 7 (1.8) 12 (2.7)
MTB-negative, n (%) 367 (97.6) 382 (98.2) 425 (96.3)
MTB RIF-sensitive, n 9 - 11
MTB RIF-resistant, n 0 - 1
Performance analysis v. culture as 
the reference
Specimens, n Comparator 
test
374 345
Sensitivity, % (95% CI) 33.3 (7.9 - 69.9) 62.5 (24.7 - 91.0)
Specificity, % (95% CI) 99.5 (98.0 - 99.9) 99.1 (97.4 - 99.8)
PPV, % (95% CI) 66.0 (15.4 - 93.5) 62.5 (24.7 - 91.0)
NPV, % (95% CI) 98.4 (96.5 - 99.4) 99.1 (97.4 - 99.8)
LPA = line probe assay.
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